Loxo Oncology Inc. said the company has entered into an agreement to purchase the Bruton’s tyrosine kinase inhibitor program from RedxPharma Plc. The lead candidate from this program is expected to enter clinical development in 2018. Under the terms of the agreement, Loxo Oncology has made a $40 million payment to Redx Pharma Plc for the full acquisition of the BTK discovery program, including lead candidate LOXO-305 (formerly RXC005). Loxo Oncology is not subject to milestone or royalty obligations.
Urologic oncologist Wayne Brisbane thought his patient might be a good candidate for focal therapy.
